Pharmacokinetics of Edoxaban in Geriatric Patients with Atrial Fibrillation

Atrial fibrillation affects nearly half of geriatric inpatients, with edoxaban frequently used for stroke prevention. However, geriatric patients are underrepresented in drug trials with edoxaban. The limited data and high pharmacokinetic variability result in using this high-risk medication without a full understanding of its exposure in this population. This dataset aims to characterize the dose–exposure relationship and predict the sufficiency of current fixed-dose guideline for geriatric patients. We conducted a single-center prospective PK study in geriatric inpatients who prescribed with routine edoxaban. Seventeen frail geriatric patients (median age 87 years, IQR 83–90) receiving routine edoxaban contributed a total of 85 steady-state PK samples.